FP-208

FP-208 is an orally bioavailable small molecule dual inhibitor targeting Colony-stimulating factor 1 receptor (CSF-1R) and Vascular endothelial growth factor receptor 2 (VEGFR2). Developed by Beijing Fulong Kangtai Biotechnology, it is designed to modulate the tumor microenvironment and inhibit tumor progression through two distinct pathways. By inhibiting CSF-1R, FP-208 reduces the recruitment and polarization of pro-tumorigenic M2-type tumor-associated macrophages (TAMs), thereby alleviating immune suppression within the tumor. Simultaneously, its inhibition of VEGFR2 suppresses tumor-associated angiogenesis, cutting off the blood supply necessary for tumor growth and metastasis. This dual-action approach is intended to provide synergistic anti-tumor activity in patients with advanced solid tumors who have failed standard therapies.